Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | TRPC5 | Q9UL62 | 4/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.36 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | GNRHR | P30968 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22411225 | 0.77 | RET (0.35) | KDR | |
| SCHEMBL21807290 | 0.76 | KDR (0.39) | KDRKCNH2TRPC5SIGMAR1 | |
| SCHEMBL29329343 | 0.75 | TRPC5 (0.41) | KDRKCNH2TRPC5TRPA1 | |
| SCHEMBL21807245 | 0.74 | TRPC5 (0.44) | KDRTRPC5 | |
| SCHEMBL21003185 | 0.74 | CHRM3 (0.47) | KDRKCNH2SIGMAR1 | |
| SCHEMBL31574307 | 0.74 | ADRA2A (0.39) | KDRKCNH2TRPC5SIGMAR1 | |
| SCHEMBL21807188 | 0.74 | ADRA2A (0.39) | KDRKCNH2TRPC5SIGMAR1 | |
| SCHEMBL21807225 | 0.74 | TRPC5 (0.55) | KDRKCNH2TRPC5TRPA1 | |
| SCHEMBL21807623 | 0.74 | TRPC5 (0.40) | KDRKCNH2TRPC5HTR1ASLC6A2 | |
| SCHEMBL29090296 | 0.74 | KDR (0.41) | KDRKCNH2TRPC5TRPA1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113939295-B | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-4414365-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-3852533-B1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO INC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3852533-B1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220024917-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220024917-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-01-27 | — | — | US | disclosed |
| EP-3941475-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3852533-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| US-11046690-B2 | Pyridazinones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046690-B2 | Pyridazinones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| WO-2020191056-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020191056-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-20200283437-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-09-10 | — | — | US | disclosed |
| US-10654850-B2 | Pyridazinones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-10654850-B2 | Pyridazinones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20200102301-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-04-02 | — | — | US | disclosed |
| WO-2020061162-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024917-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | ATP6V1B1, GLS, REN | KDR 3432/4885KCNH2 587/4885TRPC5 2486/4885 |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GLS, ATP6V1B1, PDXK | KDR 3790/4885KCNH2 966/4885TRPC5 3626/4885 |
| US-20200102301-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | ATP6V1B1, GLS, REN | KDR 3432/4885KCNH2 587/4885TRPC5 2486/4885 |
| US-11046690-B2 | Pyridazinones and methods of use thereof | ATP6V1B1, GLS, REN | KDR 3432/4885KCNH2 587/4885TRPC5 2486/4885 |
| US-20200283437-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | ATP6V1B1, GLS, REN | KDR 3432/4885KCNH2 587/4885TRPC5 2486/4885 |
| US-10654850-B2 | Pyridazinones and methods of use thereof | ATP6V1B1, GLS, REN | KDR 3432/4885KCNH2 587/4885TRPC5 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.